▼Atovaquone + proguanil for malaria prophylaxis
- 1 October 2001
- journal article
- research article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 39 (10), 73-75
- https://doi.org/10.1136/dtb.2001.391073
Abstract
▼Atovaquone + proguanil* (Malarone - GlaxoSmithKline) is a fixed-dose combination of two antiparasitic drugs. In 1996, it was licensed in the UK for the treatment of acute, uncomplicated falciparum malaria. Earlier this year, the combination was licensed additionally for prophylaxis of falciparum malaria. The manufacturer claims that, when used for prophylaxis, atovaquone + proguanil "offers 97% efficacy with a side effect profile similar to placebo". Here, we assess these claims and review the place of atovaquone + proguanil as prophylaxis for non-immune people travelling from the UK.Keywords
This publication has 7 references indexed in Scilit:
- Atovaquone‐Proguanil versus Mefloquine for Malaria Prophylaxis in Nonimmune Travelers: Results from a Randomized, Double‐Blind StudyClinical Infectious Diseases, 2001
- Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind studyThe Lancet, 2000
- A Mechanism for the Synergistic Antimalarial Action of Atovaquone and ProguanilAntimicrobial Agents and Chemotherapy, 1999
- Efficacy and Safety of Atovaquone/Proguanil as Suppressive Prophylaxis for Plasmodium falciparum MalariaClinical Infectious Diseases, 1998
- Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in childrenThe Lancet, 1998
- Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malariaJournal of Antimicrobial Chemotherapy, 1995
- Paper: Researches on paludrine (M.4888) in Malaria An experimental investigation undetaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, AustraliaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1946